FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA;SERVIZO GALEGO DE SAÚDE (SERGAS);UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
发明人:
José Ramón GONZÁLEZ JUANATEY,Rosa Mª BERMEJO AGRA,Sonia EIRAS PENAS
申请号：
US16488067
公开号：
US20200064358A1
申请日:
2018.02.28
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention offers a solution to the lack of a novel and efficient method capable to predict the outcome of patients with HF. In this context, patients with a bad prognosis are expected to be hospitalized or die in the incoming years following the diagnosis of HF, due to the HF, or due to a complication of the HF. This method is based on the concentration of Orosomucoid (APG) and Omentin in an isolated blood sample from the patient. In this sense, a high concentration of AGP and a low concentration of Omentin in blood are associated with a bad prognosis. This improved method of prognosis is aimed to help on the design of the most appropriate treatment for the patient.
